New development in the treatment of psoriasis--infliximab.
TNF-alpha may have an impact on principal pathological phenomena in psoriatic skin through inducing inflammatory cells migration from blood vessels. It follows that blockade of TNF-alpha should diminish inflammation and normalize keratinocyte proliferation in psoriasis. Infliximab is a mouse-human chimeric monoclonal antibody that neutralizes the biologic activity of tumor necrosis factor alpha (TNF-alpha) by binding to the soluble and transmembrane forms of this cytokine and inhibiting its binding to the receptors. We present literature data concerning both application of infliximab in patients with psoriasis and its side effects.
Department of Dermatology, Medical University of Lublin.
Aldona
A
Pietrzak
Grazyna
G
Chodorowska
Iwona
I
Jazienicka
Agnieszka
A
Junak-Bojarska
Jacek
J
Roliński
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab